Q BioMed Inc.
QBIO
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -88.08% | -42.45% | 278.89% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -88.08% | -42.45% | 278.89% | -- |
| Cost of Revenue | -96.62% | -6.85% | -10.03% | 56.90% | 82.02% |
| Gross Profit | -327.27% | -460.11% | -43.06% | 7,078.57% | 102.71% |
| SG&A Expenses | -59.88% | -61.48% | -47.50% | -32.93% | -48.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.10% | -66.53% | -51.00% | -40.53% | -47.29% |
| Operating Income | 61.79% | 65.14% | 51.24% | 48.46% | 50.48% |
| Income Before Tax | 68.47% | 211.24% | 55.52% | 33.41% | 7.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.47% | 211.24% | 55.52% | 33.41% | 7.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.47% | 211.24% | 55.52% | 33.41% | 7.53% |
| EBIT | 61.79% | 65.14% | 51.24% | 48.46% | 50.48% |
| EBITDA | 62.46% | 65.64% | 51.64% | 48.79% | 50.75% |
| EPS Basic | 90.67% | 139.87% | 55.92% | 25.49% | 23.11% |
| Normalized Basic EPS | 89.30% | 144.49% | 78.13% | 46.92% | 37.52% |
| EPS Diluted | 90.67% | 137.78% | 56.43% | 25.49% | 23.11% |
| Normalized Diluted EPS | 89.30% | 144.49% | 78.13% | 46.92% | 37.52% |
| Average Basic Shares Outstanding | 267.39% | 150.55% | 62.32% | 25.57% | 20.09% |
| Average Diluted Shares Outstanding | 267.39% | 150.55% | 62.32% | 25.57% | 20.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |